Since morbidity and mortality associated with hematologic malignant diseases in elderly patients is higher than that in younger patients, 1 elderly patients are less likely to be candidates for allo-SCT, due to the facts that they are more likely to have comorbid organ conditions, either clinically or subclinically, which results in a higher rate of procedure-related mortality, 2 and that they are less likely to have HLA-matched related donors available, as siblings also tend to be elderly.
The development of reduced-intensity (RI) conditioning for transplants, which results in less toxicity and depends largely on GVL effects rather than high-dose therapy to eliminate leukemic cells, has been shown to allow elderly patients to undergo allo-SCT. [3] [4] [5] The use of umbilical cord blood transplantation (UCBT) for adults has been increasing due to the potential advantage of rapid availability and the lower risk of GVHD, thus permitting less stringent HLA matching. 4, 5 RI-UCBT for adults, mostly elderly patients, has been increasingly reported and shown to be applicable. 6, 7 However, there has been no clear description on the upper age limit of receiving allo-SCT, and it varies among institutes at this moment. We report here an 82-year-old man with refractory AML who had successfully treated with RI-UCBT.
The patient was diagnosed as AML (M5b) with adverse risk karyotype (46, XY, À7, þ 8) and complicated with disseminated intravascular coagulation (DIC). Although DIC was resolved soon after remission induction therapy consisted of idarubicin and cytarabine, and the patient achieved hematological remission, the disease subsequently progressed with lung infiltration and systemic skin tumor formation ( Figure 1a ). Immunohistochemical analysis of skin tumor showed positive for CD45, myeloperoxidase, and CD68 consistent with leukemic cell infiltration. Skin and lung infiltration was refractory to following high-dose Ara-C-containing chemotherapy. At 4 months after diagnosis of AML, following careful discussion and consent among the patient, his family and transplant staff, he received an RI-UCBT using two antigen-and three allele- 2 was administered from day 1 until neutrophil engraftment. On day 14, the patient developed erythema, fever (39 1C) and diarrhea, and was diagnosed as having preengraftment immune reactions (PIR). 8 The symptoms disappeared immediately after initiation of methylprednisolone 0.5 mg/kg for 3 days. There was no episode of bacterial infection during neutropenia. ANC recovered to 0.5 Â 10 9 per liter on day 25, and platelet count reached 2.0 Â 10 9 per liter on day 64. Complete donor-cell chimerism was confirmed on day 27 by BM analysis using short tandem repeat-PCR method. Human herpesvirus-6 limbic encephalitis developed on day 17, which was successfully managed with foscarnet. The regimen-related toxicities observed were mucositis (grade 2), nausea (grade 2), renal dysfunction (grade 2) and diarrhea (grade 1), according to the National Cancer Institute Common Toxicity Criteria version 3.0. Acute GVHD of grade III (gut: stage 2) on day 46 was observed, but successfully managed with oral beclomethasone dipropionate. He finally achieved CR in BM, and his lung lesion and skin tumors also disappeared (Figure 1b) . He was discharged from hospital on day 123 after RI-UCBT. To our surprise, his level of performance status got improved thereafter, almost as score 1 measured by ECOG PS scoring system, and returned to his work in 1 month after discharge. In the meantime, chronic GVHD of limited type developed, which was managed without treatment. One year after RI-UCBT, unfortunately, his disease relapsed and he died from disease progression 1 month later.
This remarkable case told us two important issues. First, some, may be not all, patients older than 80 years still can tolerate RI-UCBT. TRM has been shown to be correlated with several factors including age, or more comprehensively, the number of coexisting comorbidities. 9 According to our previous report, those older than 54 years showed cumulative incidence of TRM reaching to approximately 50%, and most of TRM occurred early period post-UCBT. 10 This patient had also faced life-threatening events, such as PIR or viral encephalitis, and was successfully managed by corticosteroid and foscarnet. In allo-SCT settings, there are always several factors that cannot be modulated intentionally, and there may have been good coincidences for him to reach this successful outcome. Nevertheless, this case strongly claims higher age should not be the single determinant of not performing allo-SCT. Second, the most powerful antileukemic activity was observed with RI-UCBT. Although, the patient had finally disease relapse, it was obvious that only RI-UCBT sufficiently suppressed leukemic cells and gave him a sustained CR so that he had enough time to return to his job. Although CB has been shown to have functionally immature immune cells, it showed its extremely powerful anti-leukemic activity even from the early period post transplant, as the patient's skin lesion had never disappeared during induction chemotherapy including highdose Ara-C.
Whether the clinical course of this case can be applicable to all aged patients or this is exceptional case needs to be investigated carefully. The indication of allo-SCT for those who are elderly has to be determined individually with extremely careful and repeated discussion with patients, families and transplant staff. Nevertheless, the indication of allo-SCT should not be determined by age as a sole factor. Otherwise, elderly patients may lose chance of cure or good disease control, by not performing toxic yet powerful treatment, such as transplant.
